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Abstract: Rho GTPases, including Rho, Cdc42, Rac and ROP subfamilies, are key signaling molecules
in RNA polymerase II (Pol II) transcriptional control. Our prior work has shown that plant ROP and
yeast Cdc42 GTPases similarly modulate Ser2 and Ser5 phosphorylation status of the C-terminal
domain (CTD) of the Pol II largest subunit by regulating CTD phosphatase degradation. Here,
we present genetic and pharmacological evidence showing that Cdc42 and Rac1 GTPase signaling
modulates a similar CTD Ser2 and Ser5 phosphorylation code in cultured human cancer cells. While
siRNA knockdown of Cdc42 and Rac1, respectively, in HeLa cells increased the level of CTD Ser
phosphatases RPAP2 and FCP1, they both decreased the level of CTD kinases CDK7 and CDK13.
In addition, the protein degradation inhibitor MG132 reversed the effect of THZ1, a CDK7 inhibitor
which could decrease the cell number and amount of CDK7 and CDK13, accompanied by a reduction
in the level of CTD Ser2 and Ser5 phosphorylation and DOCK4 and DOCK9 (the activators for Rac1
and Cdc42, respectively). Conversely, treatments of Torin1 or serum deprivation, both of which
promote protein degradation, could enhance the effect of THZ1, indicating the involvement of protein
degradation in controlling CDK7 and CDK13. Our results support an evolutionarily conserved
signaling shortcut model linking Rho GTPases to Pol II transcription across three kingdoms, Fungi,
Plantae and Animalia, and could lead to the development of a potential synthetic-lethal strategy in
controlling cancer cell proliferation or death.
Keywords: Rho; Rac1; Cdc42; Pol II; CTD code; CDK7; DOCK4; DOCK9; THZ1; Torin1
1. Introduction
Regulation of gene expression is essential for cellular activities in response to intracellular cues
and extracellular signals. Ras superfamily small GTPases, including Ras and Rho families, act as key
signaling switches in regulating gene expression, and consequently deregulation of these signaling
GTPases is frequently associated with many diseases including cancer [1–5]. There are two models
regarding Ras and Rho GTPase control of RNA polymerase (Pol) II transcription: the well-known
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classical or “indirect” model, and the recently re-emerged direct or “shortcut” model [6]. The classical
model has been described in genetics and cell biology textbooks and literature and presented as a
paradigm in oncogenic signaling networks. In this model, activation of Ras or Rho GTPases causes a
cascade of MAP kinase phosphorylation events in the cytoplasm, leading to translocation of MAPK
into the nucleus and activation of sequence-specific transcription factors. In contrast, the shortcut
model allows activated GTPases to target protein kinase A or proteasome to regulate a component of
Mediator [7] or Pol II [8]. Given that the shortcut model does not involve the MAP kinase cascade and
instead directly regulates Pol II or its components, this model has a potential of efficiently regulating
transcription so as to rapidly bring about the broad changes in gene expression in response to dynamic
intracellular and extracellular changes [6–8].
In our prior work, we have found that Rho family GTPases, including ROP2/4 in the Arabidopsis
model plants and Cdc42 in fission yeast, modulate the phosphorylation status of Ser2 and Ser5 in the
C-terminal domain (CTD) of RPB1, the largest subunit of Pol II, effecting gene expression and the
control of cell shape, cell size and cell number [8]. The Pol II CTD contains various number of the
heptad peptide (Y1S2P3T4S5P6S7) repeat, ranging from 29 repeats in fission yeast and 34 in Arabidopsis
to 52 in humans [9–12]. Dynamic post-translational modifications of these seven residues in each
repeat, in particular phosphorylation of Ser2 and Ser5, constitutes a very complex pattern called the
“CTD code”, which is critical for completing key steps of the transcription cycle [9–12]. The CTD code is
created and maintained by several CTD kinases and CTD phosphatases. Using genetic and biochemical
approaches, we have shown that elevation of the CTD Ser2 and Ser5 phosphorylation status caused
by activation of ROP2 and Cdc42 GTPases is mediated by degradation of CTD phosphatases, CPL1
in Arabidopsis or Fcp1 in yeast [8]. However, whether these Rho GTPases also regulate CTD kinases
remains to be investigated.
The similarity in the CTD Ser2 and Ser5 phosphorylation pattern and its underlying biochemical
mechanism (degradation of CTD phosphatases) observed in both Arabidopsis and yeast strongly indicate
that the Rho-Pol II shortcut model of transcriptional control is evolutionarily conserved in eukaryotic
organisms. Therefore, we hypothesize that human cells likely use Rho family GTPases to modulate a
similar CTD code. However, humans, plants and yeast are separated by a billion years of evolution,
and thus it is also possible that human cells have adopted an overlapping and yet somehow distinct
mechanism in the Rho signaling-mediated CTD code modulation. To test these hypotheses, we used
various GTPase inhibitors and knockdown of Rac1 and Cdc42 to study the Pol II CTD Ser2 and Ser5
phosphorylation patterns. Our results suggest that Rac1 and Cdc42 GTPase signaling in cultured
human cancer cells similarly modulates the CTD Ser2 and Ser5 phosphorylation status. In addition,
while these two GTPases suppress different CTD phosphatases, they both increase the level of CTD
kinases CDK7 and CDK13. Interestingly, our results from the combined treatments of a covalent CDK7
inhibitor THZ1 and chemicals that inhibit or stimulate protein degradation imply a potential role for
THZ1 in degrading CDK7, CDK13 and activators of Rac1 (DOCK4) and Cdc42 (DOCK9), which can
potentially lead to lower activity of Rac1 and Cdc42 and thus forms a possible feedback regulatory
loop in the proposed Rho-Pol II signaling shortcut model.
2. Materials and Methods
2.1. Human Cancer Cell Cultures
Human prostate DU145 and cervical carcinoma HeLa cell lines were acquired from the American
Type Culture Collection (ATCC), maintained per ATCC protocols and utilized within six months
of thawing. Cell lines were grown in a humidified atmosphere at 37 ◦C with 5% CO2, using MEM
medium (Gibco) supplemented with 10% fetal bovine serum (Corning) and 1% Pen Strep antibiotics
(Gibco). The culture medium was replaced every other day.
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2.2. siRNA Transfection
Cdc42 and Rac1 siRNA were designed and supplied by OriGene Technologies. For Cdc42 silencing,
a mixture of 3 unique 27-mer (rArCrArArArUrUrUrCrCrArUrCrGrGrArArUrArUrGrUrACC,
rCrCrArCrArArArCrArGrArUrGrUrArUrUrUrCrUrArGrUCT and rGrGrArGrArArCrCrArUrArUrAr
CrUrCrUrUrGrGrArCrUTT) siRNA duplexes (OriGene, SR300714) was used. For Rac1 silencing,
a mixture of 3 unique 27-mer (rGrGrArArCrUrArArArCrUrUrGrArUrCrUrUrArGrGrGrATG,
rArCrArUrUrGrUrArCrUrGrUrArArUrGrGrArGrUrGrArGCG and rGrUrArGrUrUrCrUrCrArGr
ArUrGrCrGrUrArArArGrCrAGA) siRNA duplexes (OriGene, SR303958) was used. The SiLentFect
(BIO-RAD) lipid reagent was used for transfection, and the experiments were performed by following
the recommended protocol.
2.3. Inhibitor Treatments
All inhibitors were dissolved in DMSO, and the control contained the DMSO only. Ten µM
farnesylthiosalicylic acid (FTS; Sigma, SML1166), 5 µM Y16 (Sigma,SML0873), 10 µM Ehop-016 (Sigma,
SML0526) and 2 µM ML141 (Sigma, SML0407), were used as Ras, Rho, Rac and Cdc42 GTPase inhibitors,
respectively, for 48 hr in HeLa and DU145 cells. For THZ1 and MG132 treatments, HeLa cells were
treated by 100 nM THZ1 (MCE, 80013) and 40 µM MG132 (ChemCruz, sc-201270) for 8 hr. For Torin1
and serum depletion treatments, HeLa cells were treated with 100 nM Torin1 (MCE, HY-13003), serum
deprivation, or their combination with 100 nM THZ1 for 8 hr for analyzing protein level using Western
blot and for 24 or 48 hr for observing cell number.
2.4. Western Blot
Cells were collected and disrupted with RIPA buffer (Pierce IP lysis buffer; Thermo Scientific™; Cat.
#87787). Total protein levels were quantified using Pierce™BCA Protein Assay Kit (Thermo Scientific™).
Standard Western blot procedure was used, i.e., protein samples were separated by SDS-PAGE and
electrophoretically transferred onto PVDF membranes. The following primary antibodies were
used for protein detection: anti-Ser5p (Abcam, ab5131), anti-Ser2p (Abcam, ab5095), anti-Ser7p
(Active Motif, Clone 4E12), anti-CTD (Abcam, ab26721), anti-α-tubulin (Sigma, T6074), anti-DOCK4
(Bethyl Laboratories, A302-263A), anti-DOCK9 (Bethyl Laboratories, A300-530A), anti- CTDP1/FCP1
(Bethyl Laboratories, A301-172A), anti- RPAP2 (Proteintech, 17401-1-AP), anti-Cdc42 (Santa cruz,
B-8, sc-8401), anti-RAC1 (Proteintech, 24072-1-AP), anti-CDK7 (Bethyl Laboratories, A300-405A) and
anti- CDC2L5/CDK13 (Bethyl Laboratories, A301-458A). The following secondary antibodies were
used: stabilized Goat anti-Mouse HRP-Conjugated (Pierce, 1858413), stabilized Goat anti-Rabbit
HRP-Conjugated (Pierce, 1858415) and Goat anti-Rat HRP Conjugated (Thermo, 31470). After antibody
incubation, the membrane was incubated with the chemiluminescent substrate (Thermo, 34096) by
following the manufacturer’s protocol. Signal intensity was acquired by exposure to X-ray film. For
membrane stripping and re-probing, a mild stripping method was used by following Abcam’s protocol.
2.5. Quantitative Analysis of Western Blots and Cell Counting
For protein quantification, ImageJ software was used to quantify the bands in Western blots. The
ratio of each protein band relative to tubulin, an internal loading control, was derived. The relative
abundance of proteins in treatment groups was obtained by normalizing the ratio against that in the
control group, which was set as 1.0. Two-way analysis of variance (ANOVA) with protein and treatment
interaction was performed. Multiple pairwise comparisons between treatment group differences
for each protein were obtained using the Tukey Honest Significant Differences method with the R
function TukeyHSD(). For cell counting, cell images were captured with a Nikon confocal spinning
disk microscope. Each image stands for one separate vision field. For each treatment, six individual
images were used for cell counting, without any image cropping or modification. Hela cells with intact
morphology and clear structure were counted. The average cell number of all replicates in the control
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group was set as 100, and the treatment groups were then normalized against the control average.
One-way ANOVA analysis was used to assess mean cell number differences between treatment groups
and adjusted p-values were obtained using the R function TukeyHSD(). All the data are presented as
means and standard error of means (SEM), with * indicating adjusted p<0.05 and ** adjusted p<0.01.
3. Results
3.1. Treatments by Rho/Rac/Cdc42 Inhibitors Decreased the Pol II CTD Ser2 and Ser5 Phosphorylation Levels
To gain initial insights into the possible modulation of the CTD code by Rho signaling in human
cells, we used the relatively specific inhibitors for RhoA, Rac and Cdc42 in two human cancer cell
lines: the prostate cancer DU145 cell line, and the cervical carcinoma HeLa cell line. We also included
Ras GTPase inhibitor in the experiment as a comparison, given that Ras and Rho family GTPases all
have been implicated in cancer [2–5]. As shown in Figure 1, the inhibitors overall had some varying
impacts in CTD Ser2 phosphorylation (Ser2P) and Ser5 phosphorylation (Ser5P) levels, depending
on the types of inhibitors and cancer cell lines. For example, the Ras antagonist farnesylthiosalicylic
acid (FTS) [13] was effective to reduce Ser2P, Ser5P and Ser7P levels in HeLa cells (Figure 1A), but the
difference in DU145 was not statistically significant (Figure 1B). In contrast, the RhoA inhibitor Y16 [14]
strongly reduced Ser2P and Ser5P levels in DU145 cells but had no significant differences in HeLa
cells compared to the control. Interestingly, Ehop-016, a Rac1 and Rac3 inhibitor [15], significantly
reduced Ser2P and Ser5P levels in both cancer cell lines, although it also slightly reduced Ser7P in
HeLa cells. ML141, a Cdc42 inhibitor [16], was also effective in reducing Ser2P and Ser5P levels
in both cancer cell lines, except that the difference in Ser5P between control and ML141 was only
marginal in HeLa cells. Overall, while inhibitors of Ras and RhoA showed differential effects in the
CTD Ser2 and Ser5 phosphorylation status depending on the cancer cell lines, inhibitors of Rac1 and
Cdc42 more consistently reduced Ser2P and Ser5P levels in both cell lines without greatly affecting
Ser7P and total RPB1 protein accumulation. Therefore, despite some variations in different cancer cell
lines, these inhibitor treatment results strongly indicate that activity of the members from each of Rho
subfamilies modulates the CTD Ser2 and Ser5 phosphorylation code in cultured human cancer cells.
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Figure 1. Inhibitors of small GTPases reduced CTD Ser2P and Ser5P levels. Cells were treated with
various inhibitors for 48 hr, and the proteins were analyzed by Western blot using Ser5P-, Ser2P-
and Ser7P-specific antibodies. (A) HeLa cells. (B) DU145 cells. FTS, farnesylthiosalicylic acid, a Ras
antagonist. Y16, a RhoA inhibitor. Ehop-016, a Rac1 and Rac3 inhibitor. ML141, a Cdc42 inhibitor.
Tubulin, the protein loading control. Quantitative analysis of the Western blot results from two
independent biological replicates was shown. Protein level in the control was set as 1.0. Significance
level is indicated by * (p < 0.05) or ** (p < 0.01) vs. control. The letter a above the column indicates a
marginal difference (p < 0.10).
3.2. Rac1 and Cdc42 Knockdown by siRNA Decreased CTD Ser2P and Ser5P Levels and Differentially Affected
Levels of CTD Phosphatases and Kinases
To substantiate the finding regarding the role of Rac1 and Cdc42 signaling in the CTD
phosphorylation code modulation, we carried out the siRNA transfection-based knockdown studies
for Cdc42 and Rac1, respectively. As shown in Figure 2A, Cdc42 siRNA treatment altered the shape of
HeLa cells, leading to the formation of some thinner, elongated cells. Such cell shape phenotype has
been reported in Cdc42-deficient fibroblastoid cells by others [17]. There was no statistical difference in
cell number between control and siRNA treatment (Supplementary Figure S1A). Western blot analysis
showed that Cdc42 siRNA reduced Cdc42 protein level by 80% (Figure 2B), indicating the effectiveness
of siRNA-mediated knockdown. We found that siRNA treatment decreased Ser2P and Ser5P levels
by approximately 70%, without affecting Ser7P and total RPB1. This result was consistent with the
Cdc42-specific inhibitor experiment (Figure 1A).
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Figure 2. siRNA-based Cdc42 knockdown modulated the CTD phosphorylation code and affected
the level of CTD phosphatases and kinases in HeLa cells. (A) HeLa cells 48 hr after Cdc42 siRNA
transfection. (B) Western blot showing the levels of Cdc42, Ser2P, Ser5P, Ser7P and CTD phosphatases
(FCP1 and RPAP2) and kinases (CDK7 and CDK13) in Cdc42 siRNA-transfected HeLa cells. Tubulin
was used as the protein loading control. Quantitative analysis of the Western blot results from two
independent biological replicates was shown. Protein level in the control was set as 1.0. Significance
level is indicated by * (p < 0.05) or ** (p < 0.01) vs. control. The letter a above the column indicates a
marginal difference (p = 0.058) compared to control.
To determine whether the decrease of the Ser2P and Ser5P level is related to the alteration of
CTD phosphatases or CTD kinases, we assessed the levels of two CTD phosphatases (FCP1 and
RPAP2) and two CTD kinases (CDK7 and CDK13). We found that the protein level for FCP1,
a Ser2 and Ser5 phosphatase [18], which is orthologous to yeast Fcp1, did not increase in Cdc42
siRNA-treated cells (Figure 2B). Instead, another CTD phosphatase, RPAP2, which acts at Ser5 [19],
had a marginal difference between siRNA-transfected cells and the control (1.9- and 3.7-fold increase in
two independent replicates, respectively). In addition, two CTD kinases, CDK7 (which phosphorylates
Ser5 and Ser7 [20]) and CDK13 (acting at Ser2 and Ser5 [21]), were both reduced by 3- to 4-fold in Cdc42
siRNA treated cells. This result indicates that Cdc42 signaling in human cells similarly modulates the
CTD Ser2 and Ser5 phosphorylation code as in plant and yeast systems, and yet it does so possibly by
inhibiting RPAP2 and activating CDK7 and CDK13.
For Rac1, we found that Rac1 siRNA transfection had a similar effect in the formation of some thin,
elongated cells siRNA (Figure 3A) as the Cdc42 siRNA treatment (Figure 2A), without affecting cell
number (Supplementary Figure S1B). Rac1 protein level was reduced by 83% (Figure 3B), demonstrating
that siRNA was effective in knocking down Rac1 expression. Similar to Cdc42 siRNA, Rac1 siRNA
also reduced Ser2P and Ser5P levels by approximately 60-70% without affecting Ser7P and total RPB1
levels. Therefore, both Cdc42 and Rac1 GTPases are involved in a similar CTD phosphorylation code
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modulation. However, in contrast to Cdc42, Rac1 siRNA caused a 2.1-fold increase in Fcp1 level without
affecting RPAP2 level (Figure 3B). With regard to CDK7 and CDK13, Rac1 siRNA similarly reduced
their levels as Cdc42 siRNA.
Figure 3. siRNA-based Rac1 knockdown modulated the CTD phosphorylation code and affected the
level of CTD phosphatases and kinases in Hela cells. (A) HeLa cells 48 hr after Rac1 siRNA transfection.
(B) Western blot showing the levels of Cdc42, Ser2P, Ser5P, Ser7P, FCP1, RPAP2, CDK7 and CDK13 in
Rac1 siRNA-transfected HeLa cells. Tubulin, the protein loading control. Quantitative analysis of the
Western blot results from two independent biological replicates was shown. Protein level in the control
was set as 1.0. Significance level is indicated by * (p < 0.05) or ** (p < 0.01) vs. control.
Taken together, the results from our siRNA transfection experiments showed that members
in the two subfamilies of Rho family GTPases, Rac1 and Cdc42, modulate the CTD Ser2 and Ser5
phosphorylation status. Furthermore, it is possibly that they act by negatively regulating the
accumulation of specific CTD phosphatases and positively regulating the accumulation of CTD kinases
CDK7 and CDK13.
3.3. Effects of THZ1 in CTD Code Modulation and Accumulation of CDK and DOCK Proteins Can Be
Reversed by MG132 Treatment
Since our prior findings have demonstrated that yeast Cdc42 and Arabidopsis ROP2 GTPases are
involved in proteasome-mediated degradation of CTD phosphatases [8], we tested whether MG132,
a proteasome inhibitor, would block the Cdc42 and Rac1 siRNA effects. However, we repeatedly
observed that mixtures of MG132 and siRNA quickly and severely arrested cell growth, which did not
allow us to collect enough cells for Western blot analysis. Thus, we decided to use a highly specific
CDK7 inhibitor, THZ1, in combination with MG132. The use of THZ1 was motivated by other groups’
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prior studies showing that THZ1 can strongly suppress cancer cell growth by inhibiting Pol II CTD
phosphorylation and consequently controlling transcription [22–25].
We first assessed whether THZ1 had a similar effect in modulating the CTD code and affecting the
CDK targets as Rac1 and Cdc42 siRNA knockdown. We observed that 100 nM THZ1 treatment for
8 hr caused HeLa cell growth to be inhibited, resulting in only 50% of the viable cells compared to
the no-THZ1 control, with dead cells floating on the surface of the medium (Figure 4A,B). Western
blot analysis showed that THZ1 caused approximately 80% reduction in Ser2P and Ser5P levels,
without affecting total RPB1 protein accumulation (Figure 4C,D), similar to Cdc42 and Rac1 siRNA
transfections. However, Ser7P level was also reduced by THZ1, unlike Rac1 and Cdc42 siRNA,
which did not impact Ser7P level. Surprisingly, THZ1 also reduced the levels of CDK7 (by 85%) and
CDK13 (by 53%), a phenomenon not reported by prior studies [22–26] but similar to the effect of Cdc42
and Rac1 siRNA-transfection (Figures 2B and 3B). We then studied whether MG132 could oppose the
effect of THZ1 in CTD code modulation and CDK7/13 accumulation. Although MG132 alone did
not affect Ser2P, Ser5P, Ser7P and total RPB1 levels, there was a trend that combining MG132 and
THZ1 (THZ1 + MG132) could increase the levels of Ser2P, Ser5P and Ser7P, compared to THZ1 alone
(Figure 4C,D). The lack of statistical differences between MG132 and THZ1 + MG132 indicates that the
inhibitory effect of THZ1 could be nullified by MG132. Similarly, although MG132 marginally reduced
the CDK7 level and did not affect CDK13, THZ1 + MG132 tended to have higher CDK7 and CDK13
levels, compared to THZ1 alone. Given the lack of differences in CDK7 and CDK13 levels between
MG132 and THZ1 + MG132, there remains a possibility that THZ1, an inhibitor of CDK7, might also
act by promoting degradation of CDK7 and CDK13, which could be opposed by MG132. Thus, these
results consistently suggest an opposing effect of MG132 on THZ1 in controlling the levels of both CTD
Ser phosphorylation and CDK7 and CDK13 proteins. Accordingly, we found that THZ1 + MG132 led
to more viable cells that remained than THZ1 alone, although MG132 itself under this condition did
not affect the HeLa cell number (Figure 4A,B).
In addition, we investigated whether THZ1 also impacted the level of guanine nucleotide exchange
factors (GEFs) for Rac1 and Cdc42. This was motivated by our observation that the loss-of-function
mutation in CAE2, which encodes an Arabidopsis plant CTD Ser5 phosphatase called CPL1 [8], increased
the level of GTP-bound, active form of ROP GTPase by 4-fold (Supplementary Figure S2). As we have
shown previously that the loss of the CPL1 function results in an increase of the CTD Ser2P and Ser5P
level [8], the current result indicates a feedback regulation of ROP2 GTPase activation by the Pol II
CTD Ser phosphorylation level. We therefore tested whether inhibition of CTD Ser phosphorylation
in HeLa cells by THZ1 would decrease the level of GEFs for Rac1 and Cdc42, and if so, whether this
effect could be reversed by MG132. As a first step, we chose to study DOCK4 and DOCK9 among a
large family of GEFs, given that DOCK4 and DOCK9 have been demonstrated to respectively activate
Rac1 and Cdc42 [27–30] and that mutations in DOCK4 [31–35] and DOCK9/Zizimin1 [36] have been
found in a number of cancers. Knockdown of DOCK4 and DOCK9 was also reported to reduce cancer
growth [37]. As shown in Figure 4C,D, THZ1 caused a 50% reduction in DOCK4 level (a statistically
marginal difference) compared to control. For DOCK9, it appeared to have a similar trend of inhibition
by THZ1 (although the 30% and 56% reduction in two independent replicates respectively was not
statistically significant). As observed for the CTD phosphorylation pattern described above, the
combined treatment of MG132 and THZ1 appeared to increase DOCK4 and DOCK9 levels compared
to THZ1 alone. In addition, the DOCK4 and DOCK9 levels were similar between MG132 alone and
MG132 + THZ1, indicating that MG132 could reverse the THZ1-caused suppression.
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Figure 4. Suppression of the THZ1 effects by MG132 treatment in HeLa cells. (A) Cells after 8
hr-treatments of 100 nM THZ1 and 40 µM MG132. (B) Quantitative analysis of cell number after
treatments. Cell number for the control average is set as 100, and all other treatment groups are
normalized to the control. Values are means and SEM of six replicates, with ** indicating significant
difference between THZ1 and three other groups (p < 0.01). (C) Western blot showing the effect of
THZ1 suppressed by MG132. Tubulin, the protein loading control. (D) Quantitative analysis of the
Western blot results from two independent biological replicates. Protein level in the control was set
as 1.0. Significance level is indicated by * (p < 0.05) or ** (p < 0.01) vs. control. The letter a above the
column indicates a marginal difference (p < 0.10) compared to control.
3.4. Serum Deprivation and Torin1 Treatments Enhanced the THZ1 Effect
The above observation that proteasome degradation inhibitor MG132 suppresses the effect of
THZ1 led us to test whether Torin1 and serum depletion, which have been shown to promote protein
degradation [38], could further enhance the impact of THZ1. Our results showed that after 24 hr
of treatment, 30% of HeLa cells remained viable with 100 nM THZ1 alone, and the combination of
100 mM Torin1 and 100 nM THZ1 caused most of the cells dead (floating on the surface of the medium)
with only 5% of HeLa cells remaining viable (Figure 5A,B). Thus, although Torin1 by itself under
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this condition did not reduce cell number compared to the control (Figure 5A,B), when combined
with THZ1, it resulted in a 6-fold further reduction of cell number compared to THZ1 alone. Serum
deprivation in combination with THZ1 had a similar effect as the combined treatment of Torin1 and
THZ1 in further reducing the number of viable cells compared with THZ1 alone. Different from
Torin1, serum deprivation alone slightly reduced the number of viable cells, which is consistent with
the notion that the serum deprivation treatment has a stronger effect in protein degradation than
Torin1 [38]. To determine whether lower doses of Torin1 could also exert an enhancement effect on
THZ1, we compared the cell number in response to various doses of Torin1 (5, 10, 25 and 50 nM) in
combination with 100 nM THZ1 (Supplementary Figure S3). Our linear regression analysis showed that
increasing the Torin1 dose was significantly related to decreasing the cell number (adjusted R2 = 0.61,
p < 0.01). Torin1 at low doses (5 and 10 nM) reduced the cell number by approximately 20%–30%
compared to the baseline control (0 nM Torin1).
We then used Western blot to study the CTD phosphorylation status and the levels of CDK7,
CDK13, DOCK4 and DOCK9. Since the 24 hr treatments of 100 nM Torin1 or serum deprivation in
combination with 100 nM THZ1 caused severe cell death, 8-hr-treated cells were instead used in this
study. Similar to its lack of effect in cell number, Torin1 alone did not cause a decrease in Ser2P, Ser5P
and Ser7P levels (Figure 5C). Although serum deprivation by itself slightly reduced cell number after
24 hr treatment (Figure 5B), it did not affect the levels of Ser2P, Ser5P and Ser7P after 8 hr treatment
(Figure 5C,D). In addition, serum deprivation showed a trend of reducing the CDK7 level, but this
difference was not statistically significant and there was no difference in CDK13 level between serum
derivation and control. Torin1 alone did not impact CDK7 and CDK13 levels. Regarding the THZ1
treatment, as described in Figure 4C,D above, it similarly reduced the CDK7 and CDK13 level in this
experiment (Figure 5C,D). In addition, we found a common trend that serum deprivation or Torin1 in
combination with THZ1 had lower levels of CDK7 and CDK13 than THZ1 alone (Figure 5D). The lack
of statistical differences between THZ1 and Torin1+THZ1 or serum deprivation+THZ1 was partly
due to the variations in the CDK7 and CDK13 protein levels in THZ1 treatment in two independent
replicates, given that the combined treatments had a smaller amount of these CDK proteins relative to
that in THZ1 treatment in both replicates. For example, compared to THZ1 alone, Torin1+THZ1 in two
replicates respectively led to 2.5- and 12.5-fold reduction in CDK7 and 2.3- and 9.1-fold reduction in
CDK13. This pattern of further reduction relative to THZ1 was also observed for Ser2P, Ser5P and Ser7P
(Figure 5D), although serum deprivation combined with THZ1 led to Ser2P and Ser5P that was barely
detectable (Figure 5C). As the total RPB1 level was not affected under this condition, the decrease of
Ser2P, Ser5P and Ser7P levels was not likely a result of global protein degradation. With regard to
DOCK4 and DOCK9, although we only observed a statistically marginal difference for DOCK4 and a
trend for DOCK9 between THZ1 and control in the initial experiment as presented in Figure 4D, THZ1
in this experiment caused a statistically significant 3-6 fold reduction in DOCK4 and DOCK9 levels
(Figure 5D). In addition, the combined treatments of THZ1 with Torin1 or with serum deprivation
appeared to further reduce DOCK4 and DOCK9 levels compared to THZ1 alone (Figure 5C,D).
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Figure 5. Enhancement of the THZ1 effect by Torin1 and serum deprivation treatments. (A) Cells
treated with 100 nM THZ1 and 100 nM Torin1 or serum depletion (-Serum) for 24 hr. (B) Quantitative
analysis of cell number after 24 hr treatments. Cell number for the control average is set as 100, and all
other treatment groups are normalized to the control. Values are means and SEM of six replicates,
with ** (p<0.01) indicating significant differences vs. control, or between treatments as indicated.
(C) Western blot showing the effect of THZ1 enhanced by Torin1 and serum depletion (-Serum) after 8-hr
treatments. Tubulin, the protein loading control. (D) Quantitative analysis of the Western blot results
from two independent biological replicates. Protein level in the control was set as 1.0. Significance
level is indicated by * (p < 0.05) or ** (p < 0.01) vs. control. The letter a above the column indicates a
marginal difference (p < 0.10) compared to control.
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4. Discussion
4.1. Modulation of the Pol II CTD Phosphorylation Code by Rho Family GTPases Is Likely Conserved in
Cultured Human Cells via Regulating CTD Kinases and Phosphatases
The shortcut model of Ras or Rho GTPase control of Pol II transcription has been supported
so far only by the evidence from the studies of yeast and Arabidopsis plant systems [7,8]. In animal
cells, there was only one early study involving a rat cardiac cell culture [39], which implicates the
impacts of Ras GTPase signaling on the Pol II overall phosphorylation levels, as radioactive isotope
labeling (rather than the CTD Ser2P- or Ser5P-specific antibodies) was used. Interestingly, this prior
study showed the importance of the CTD domain in Ras activation of transcriptional control and
reported a reduction of Cdk7 protein level in a dominant negative Ras mutant and an increase of
Cdk7 in a RasGAP (a negative regulator of Ras) mutant, indicating that Cdk7 could be a downstream
target of Ras signaling in the control of Pol II transcription. We now provide pharmacological
evidence that the CTD Ser2 and Ser5 phosphorylation status could be altered by inhibitors of Ras,
as well as Rho, Rac and Cdc42, in human cancer cell lines, supporting a common theme for the Ras
superfamily of GTPases-mediated modulation of the Pol II CTD code. Furthermore, our genetic
evidence obtained by using siRNA-mediated knockdown of Rac1 and Cdc42 convincingly demonstrate
a similar modulation of the CTD Ser2 and Ser5 phosphorylation code by these two Rho GTPases.
Therefore, our results described here together with the evidence previously reported in yeast and
Arabidopsis model systems [8] suggest that the shortcut model of Pol II transcriptional control by
Rho family GTPases is likely conserved across three of the eukaryotic kingdoms, Animalia, Plantae
and Fungi.
Our prior work in yeast and Arabidopsis has shown that the proteasome-mediated degradation
of a CTD Ser5 phosphatase CPL1 in Arabidopsis and a Ser2 phosphatase Fcp1 in yeast is at least part
of the mechanism by which Rho family GTPases modulate the CTD Ser2 and Ser5 phosphorylation
code [8]. The results reported here suggest differential regulation of CTD phosphatases by Cdc42 and
Rac1 in human cancer cell culture. For example, Cdc42 siRNA knockdown increased accumulation of
RPAP2, a CTD Ser5 phosphatase [19], but not FCP1, a Ser2 and Ser5 phosphatase [18], which is an
ortholog of yeast Fcp1. This suggests that Cdc42 signaling likely suppresses RPAP2 but not FCP1.
In contrast, Rac1 likely suppresses FCP1 but not RPAP2. Note that the Ser specificity for FCP1 and
RPAP2 was demonstrated in vitro, but inactivation of the presumably Ser5-specific CTD phosphatase
CPL1 in Arabidopsis could also lead to an increase of Ser2P level in vivo for the reasons not yet
known [8]. Therefore, the decrease of Ser2P and Ser5P levels in Cdc42 and Rac1 siRNA-treated cells
could be explained at least partially by the increase of RPAP2 and FCP1, respectively. Another possible
explanation is the alteration of a CTD Ser5- and Ser7-kinase CDK7 and a Ser2 kinase CDK13, given that
both were reduced in Cdc42 and Rac1 knockdown cells. Taken together, these results suggest that in
cultured human cancer cells, signaling by Cdc42 and Rac1 differentially suppresses CTD phosphatases
and commonly increases the level of CTD kinases, which together likely contribute to creation and
maintaining of the CTD Ser2 and Ser5 phosphorylation code. One limitation is the use of Ser-specific
antibodies in this work, and thus future work using tandem mass spectrometry-based methods [40,41]
is needed to profile the dynamic CTD Ser2 and Ser5 phosphorylation status in each peptide repeat
along target genes and dissect the mechanisms by which inactivation of Rac1 and Cdc42 controls the
level of CTD phosphatases and CTD kinases in an opposite fashion.
4.2. A Hypothetical Model for the Rho-Pol II signaling shortcut in transcriptional control in cultured
human cells
The decrease of DOCK4 and DOCK9 after the THZ1 treatment is an interesting observation in our
study. We should point out that the use of two independent biological replicates is a limitation for
Western blot experiments in our study and the statistical power would increase if more replicates were
performed. Indeed, when two sets of the Western blot results for the THZ1 treatment from Figures
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4D and 5D were combined, thus representing a total of four replicates, we found that THZ1 caused a
statistically significant decrease in DOCK4 and DOCK9 levels, together with significantly reduced CTD
Ser2/4/7 phosphorylation and CDK7/13 accumulation (Supplemental Figure S4). This is different from
statistically marginal differences for DOCK4 (Figure 4D) and Ser2P (Figure 5D) or the lack of statistical
difference for DOCK9 (Figure 4D). Given the impact of THZ1 in transcriptional control via CDK7
inactivation, the reduction of DOCK4 and DOCK9 is likely caused by transcriptional suppression.
DOCK4 has been shown to be a GEF, which activates Rac1 and DOCK9 to be a GEF for activating
Cdc42 [27–30], and thus we hypothesize that the reduction in DOCK4 and DOCK level can potentially
lead to inactivation of Rac1 and Cdc42, respectively. Together with the observed suppression of CDK7
and CDK13 by the knockdown of Rac1 and Cdc42, we propose a hypothetical model (Figure 6) in which
signaling of Rac1 and Cdc42 to Pol II transcriptional control possibly involves a feedback regulatory
loop: Inactivation of Rac1 and Cdc42 leads to inhibition of CDK7 and CDK13 and promotion of FCP1
or RPAP2, which together reduce the CTD Ser phosphorylation status and suppress transcription of
DOCK4 and DOC9. Consequently, less DOCK4 and DOCK9 proteins accumulate, which ultimately
results in stronger or sustained inactivation of Rac1 and Cdc42. Conversely, activation of these GTPases
would be expected to increase CDK7/13, causing up-regulation of DOCK4/9, and as a result stronger
activation of Rac1 and Cdc42. This type of feedback regulatory loop would enable the cells to rapidly
respond to external stimuli or internal cues in regulating gene expression. Indeed, we have shown
that elevation of the CTD Ser2P and Ser5P (caused by the mutation in the CPL1-encoed CTD Ser5
phosphatase gene) did lead to activation of ROP GTPase in Arabidopsis plants (Supplementary Figure
S2), and thus future research is necessary to determine whether reduction of DOCK4 and DOCK9 in
human cancer cell culture indeed leads to lower activity of Rac1 and Cdc42, respectively. If this is
case, then it will be important to reveal which of Rac1 or Cdc42 signaling components are involved in
differential regulation of CTD kinases and phosphatases.
Figure 6. A hypothetical model for the Rho-Pol II signaling shortcut in transcriptional control in
cultured human cells. Once activated by extracellular signals, Rac1 and Cdc42 GTPases positively
control the degradation of CTD kinases (CDK7 and CDK13) but negatively and differentially control
the degradation of CTD phosphatases (FCP1 for Rac1 and RPAP2 for Cdc42) in modulation of the Pol II
CTD code (Ser2P and Ser5P). Feedback regulation of DOCK4 and DOCK9, the activators of Rac1 and
Cdc42, respectively, is hypothesized to be achieved by transcriptional control of these DOCK genes
(indicated by dotted green arrows).
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4.3. Potential for Developing a Synthetic-Lethal Cancer Therapy
Another intriguing finding from our study is the opposing effects of MG132 and Torin1 on THZ1.
THZ1 was discovered as a covalent CDK7 inhibitor [22], with a promising potential in cancer treatment.
However, we unexpectedly but consistently observed a reduction of the CDK7 and CDK13 protein
level in THZ1-treated cells (Figure 4C,D, Figure 5C,D, and Supplemental Figure S4), which was not
reported in several studies that examined CDK7 levels after THZ1 treatment [22–26,42]. In a couple of
studies [23,43], although CDK7 protein level was not reduced, a decline in phosphorylated CDK7 was
observed instead. In addition, these two studies reported a decrease in the level of other CDKs. For
example, one study found a reduction of CDK2 [43]. In the other study, Chipumuro et al. reported
a lower amount of both total CDK9 protein and phosphorylated form of CDK9 following the THZ1
treatment, and they interpreted this result as an indirect effect in that THZ1-induced CDK7 inhibition
also targets CDK9 transcription [23]. However, one study did report a reduction of CDK7 after THZ1
treatment in one type of peripheral T-cell lymphoma but not in another cell type [44]. In our study, we
repeatedly found a 50%-85% reduction of CDK7 and CDK13 levels following 8-hr treatment of THZ1
at a normal concentration (Figure 4C,D and Figure 5C,D). Given that THZ1 might also cross-react with
CDK12 and CDK13 at higher concentrations [22], reduction of the CDK13 protein level might not be
indirectly caused by CDK7-mediated transcriptional suppression. Importantly, we observed that the
THZ1-caused reduction of CDK7 and CDK13 levels could be reversed by the MG132 treatment and
enhanced by treatments of Torin1 and serum deprivation, accompanied by the consistent changes in
the CTD Ser2P, Ser5P and Ser7P levels and cell number. Therefore, our result strongly implies the
involvement of proteasome-mediated degradation of CDK7 and CDK13 by THZ1. Of note, the reversal
by MG132 of THZ1 effects was also reported by another study [42]. In that study, Wang et al. found
that that MG132 opposed the effect of THZ1 in cyclin B accumulation and chromosomal misalignment,
although the CTD Ser phosphorylation status or CDK7 level was not examined. Thus, future work is
needed to determine whether THZ1 might interfere with another protein, which is involved in protein
degradation and competitively bound by MG132, or whether THZ1 indirectly causes transcriptional
upregulation of a proteasome component, which is subjected to MG132 blocking.
Most importantly, we found that combining THZ1 with Torin1 or serum deprivation had a trend
of further reducing CDK7/13 and Ser2P/5P/7P levels and caused the death of much larger number
of cultured cancer cells compared to THZ1 alone. Although Torin1 by itself (up to 100 nM) had no
impact in our treatment regime, it could significantly enhance the THZ1 effect, even at much lower
doses (5-10 nM). Such synergistic effects of THZ1 with other compounds that alter p53 transcription,
receptor tyrosine kinase or hedgehog pathways were recently reported [45–47]. It is possible that the
proposed Rac1 and Cdc42 feedback regulatory loop is involved, as their activators DOCK4/9 are also
further reduced by the combined treatment of Torin1 and THZ1. Therefore, our finding might form an
important basis for developing a potential synthetic lethal therapeutic strategy that targets the activity
or degradation of CDK7 and other protein components involved in the Rho GTPase signaling shortcut
model proposed here.
5. Conclusions
In plant and yeast systems, Rho GTPase signaling has been shown to link to Pol II transcription by
modulating the CTD code, but whether this shortcut model is conserved in humans remains completely
unknown. We provided pharmacological and genetic evidence showing a similar Pol II CTD code
modulation by Cdc42 and Rac1 GTPases in cultured human cancer cells. Thus our work reported here
suggests a likely universal signaling shortcut from Rho to Pol II across the three eukaryotic kingdoms,
Fungi, Plantae and Animalia, via regulation of distinct CTD phosphatases but common CTD kinases.
Additionally, combining the treatments that promote protein degradation and a CDK7 inhibitor THZ1
has the potential for developing a synthetic-lethal therapy for more effective cancer treatment.
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impact of THZ1 on CTD Ser2/5/7 phosphorylation, CDK7/13 and DOCK4/9 levels analyzed by the aggregated data.
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